Work

Outcome of chemo-immunotherapy for extensive-stage small-cell lung cancer according to potential clinical trial eligibility: 3-year outcomes from prospective cohort study.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.8087

Authors: Motohiro Tamiya, Daichi Fujimoto, Akito Hata, Hirotaka Matsumoto, Jun Sugisaka, Toshihide Yokoyama, Yoshihiko Taniguchi, Junji Uchida, Satoshi Hara, Go Saito, Satoru Miura, Hidekazu Suzuki, Satoshi Ikeda, Ryota Hiraoka, Masaaki Yanai, Nobuyuki Yamamoto, Hiroaki Akamatsu

Institutions: Osaka International Cancer Institute, Wakayama Medical University, Hyogo Prefectural Amagasaki General Medical Center, Sendai Kousei Hospital, Kurashiki Central Hospital, NHO Kinki Chuo Chest Medical Center, Toneyama National Hospital, Itami City Hospital, Chiba University, Niigata Cancer Center Hospital, Osaka Habikino Medical Center, Kanagawa Cardiovascular and Respiratory Center, Himeji Medical Center, Tottori University, Wakayama Medical University Hospital

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Chugai Pharmaceutical

OpenAlex ID: W4400037548

Cites:

Cited by:

Related to: 10